[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550406":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":61,"collaborators":24,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":24,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":24,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":46,"whyStopped":24,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University of Chicago","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"High Intensity","ACTIVE_COMPARATOR","Receives high-intensity text messaging for 2 cycles of treatment",[13],"Other: High Intensity",{"label":15,"type":10,"description":16,"interventionNames":17},"Low Intensity","Receives no texts for 1st cycle and low-intensity texts for 2nd cycle",[18,19],"Other: No Text Messagings","Other: Low Intensity Text Messaging",[21,25,29],{"type":6,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"Daily texts",[9],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"No Text Messagings","Standard Care",[15],{"type":6,"name":30,"description":31,"armGroupLabels":32,"otherNames":24},"Low Intensity Text Messaging","Weekly Texts",[15],[34],{"name":35,"affiliation":5,"role":36},"Wendy Stock","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":24,"email":42},"Clinical Trials Intake","CONTACT","1-855-702-8222","cancerclinicaltrials@bsd.uchicago.edu",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"University of Chicago Medicine Comprehensive Cancer Center","RECRUITING","Chicago","Illinois","60637","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-87.65005,41.85003,{"lat":56,"lon":55},[59,60],{"name":39,"role":40,"phone":41,"phoneExt":24,"email":42},{"name":35,"role":36,"phone":24,"phoneExt":24,"email":24},{"type":62,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100550406","using-text-messages-to-improve-oral-chemotherapy-for-adolescents-and-adults-with-acute-lymphoblastic-leukemia-100550406",false,"NCT06446661","Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia","Improving Oral Chemotherapy Adherence in Maintenance for Adolescents and Adults With Acute Lymphoblastic Leukemia Using Text Messages","Inclusion Criteria:\n\n* Age of 15-39 years-old at the time of initial ALL diagnosis\n* Diagnosed with ALL\n* Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance.\n\nExclusion Criteria:\n\n* Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages\n* Patient does not wish to participate\n* Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.","ALL","15 Years","39 Years",{"count":74,"type":75},38,"ESTIMATED","INTERVENTIONAL",[78],"NA","The purpose of this section is to learn how text message reminders might help with regularly taking chemotherapy medications for Adolescents and Adults with Acute Lymphoblastic leukemia (ALL).",[81],"Acute Lymphoblastic Leukemia",[83],"Oral Chemotherapy","2026-06-12",{"date":86,"type":87},"2026-06-15","ACTUAL",{"date":89,"type":75},"2026-12-15",{"date":91,"type":75},"2028-06-15",{"name":5,"class":6},1]